Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial

NCT07056478 is registered in ClinicalTrials.gov with Prince of Wales Hospital, Shatin, Hong Kong as lead sponsor.

NCT NCT07056478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07056478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial
Lead sponsor
Prince of Wales Hospital, Shatin, Hong Kong
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
January 1, 2030
Enrollment
130 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcopenia in elderly